Posts tagged "Annual"

Penny Stock News: Marina Biotech, Inc. (MRNA: OTCQB) | Marina Biotech to Present at the 9th Annual LD Micro Main Event

BOTHELL, WA–(Marketwired – Nov 25, 2016) – Marina Biotech, Inc. (OTCQB: MRNA) today announced that its CEO, Joseph W. Ramelli, will be presenting at the LD Micro Main Event on Thursday, December 8, 2016 at 8am PT, at the Luxe Sunsent Boulevard Hotel in Los Angeles.  Management will update investors on the synergy derived from the recent merger with IthenaPharma to deliver unparalleled targeted therapy against colorectal cancer as well as familial adenomatous polyposis (FAP).  In addition, Mr. Ramelli and Marina Biotech’s chairman, Dr. Vuong Trieu, will participate in 1-on-1 meetings with conference attendees. A copy of the investor presentation will be accessible in the investor relations section of the company’s website at http://www.marinabio.com/investors/. About Marina Biotech, Inc. Marina Biotech is a clinical stage development and commercialization company, with a pipeline focused on treating familial adenomatous polyposis (FAP) and colon cancer. In addition, Marina has a preclinical program for myotonic dystrophy, using its own unique antisense oligonucleotide chemistry and delivery capabilities. Marina Biotech Forward-Looking Statements Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially […]

Read more...

Posted by admin - November 25, 2016 at 1:08 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , ,

Penny Stock News: Localiza Rent A Car SA (LZRFY: OTCQX International Premier) | Annual corporate events calendar

Annual corporate events calendar Nov 22, 2016 OTC Disclosure & News Service Belo Horizonte – MG, Brazil This release includes additional documents. Select the link(s) below to view. Annual corporate events calendar.pdf Copyright © 2016 OTC Markets. All Rights Reserved The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases. OTC Markets Group – News, Filings & Corporate Actions

Read more...

Posted by admin - November 22, 2016 at 8:14 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , ,

Penny Stock News: Red 5 Limited (RDFLY: OTCQX International) | Results of annual general meeting

Results of annual general meeting Nov 22, 2016 OTC Disclosure & News Service WA, WA, Australia This release includes additional documents. Select the link(s) below to view. Results of agm (11.22.16).pdf Copyright © 2016 OTC Markets. All Rights Reserved The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases. OTC Markets Group – News, Filings & Corporate Actions

Read more...

Posted by admin - November 22, 2016 at 9:37 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , ,

Penny Stock News: ProMetic Life Sciences Inc. (PFSCF: OTCQX International) | ProMetic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology Annual Meeting

LAVAL, QC, Nov. 18, 2016 /PRNewswire/ – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“ProMetic” or the “Corporation“) today announced that it is presenting new data at the American Society of Nephrology’s (“ASN”) Annual Meeting currently underway in Chicago, with respect to ProMetic’s anti-fibrotic and orally active lead drug candidate, PBI-4050. “We have several presentations at this year’s ASN meeting providing further substantial evidence of PBI-4050’s ability to reduce kidney and pancreatic fibrosis and preserve their respective functions”, stated Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.  “This year, we are also presenting data on the positive effect of PBI-4050 on the kidneys of patients suffering from metabolic syndrome and type 2 diabetes (“MST2D”), evidenced by the significant reduction of biomarkers in urine.  PBI-4050’s performance in a myriad of preclinical renal models and in our phase 2 clinical trial in MST2D patients gives us great confidence for the forthcoming clinical trial in patients with Chronic Kidney Disease, which we plan to initiate early next year”, added Mr. Laurin. Clinical Poster Presentation PBI-4050 reduces Cardiovascular and Renal Biomarkers in Type II Diabetic Patients with Metabolic Syndrome (Abstract #6341) Preclinical Poster Presentation PBI-4050 Protects Against Renal Fibrosis and Improves Pancreatic […]

Read more...

Posted by admin - November 18, 2016 at 7:28 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , , , , ,

Penny Stock News: ProMetic Life Sciences Inc. (PFSCF: OTCQX International) | ProMetic presents PBI-4050’s positive effect on diabetic patients’ kidneys at the American Society of Nephrology Annual Meeting

LAVAL, QC, Nov. 18, 2016 /CNW Telbec/ – ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“ProMetic” or the “Corporation“) today announced that it is presenting new data at the American Society of Nephrology’s (“ASN”) Annual Meeting currently underway in Chicago, with respect to ProMetic’s anti-fibrotic and orally active lead drug candidate, PBI-4050. “We have several presentations at this year’s ASN meeting providing further substantial evidence of PBI-4050’s ability to reduce kidney and pancreatic fibrosis and preserve their respective functions”, stated Mr. Pierre Laurin, President and Chief Executive Officer of ProMetic.  “This year, we are also presenting data on the positive effect of PBI-4050 on the kidneys of patients suffering from metabolic syndrome and type 2 diabetes (“MST2D”), evidenced by the significant reduction of biomarkers in urine.  PBI-4050’s performance in a myriad of preclinical renal models and in our phase 2 clinical trial in MST2D patients gives us great confidence for the forthcoming clinical trial in patients with Chronic Kidney Disease, which we plan to initiate early next year”, added Mr. Laurin. Clinical Poster Presentation PBI-4050 reduces Cardiovascular and Renal Biomarkers in Type II Diabetic Patients with Metabolic Syndrome (Abstract #6341) Preclinical Poster Presentation PBI-4050 Protects Against Renal Fibrosis and Improves […]

Read more...

Posted by admin - November 18, 2016 at 6:18 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , , , , ,

Penny Stock News: Contango Ore, Inc. (CTGO: OTCQB) | Contango ORE, Inc. Announces Private Placement Results, Operational Update, Annual Meeting of Shareholders Results and Quarterly Financial Report for Period Ended September 30, 2016

Contango ORE, Inc. Announces Private Placement Results, Operational Update, Annual Meeting of Shareholders Results and Quarterly Financial Report for Period Ended September 30, 2016 Nov 17, 2016 OTC Disclosure & News Service – Contango ORE, Inc. (“CORE” or the “Company”) (OTCQB: CTGO) announced that certain holders of outstanding warrants issued in 2013 have exercised 587,500 warrants resulting in $ 5.3 million in cash net to the Company (including $ 0.8 million exercised by entities controlled by the Company’s President, Brad Juneau). The holders of these warrants were offered a 10% discount to early exercise the warrants for cash to provide the Company with financial flexibility. In addition, in an unrelated transaction, 62,500 warrants were exercised in a cashless exercise at their original $ 10 exercise price, leaving 580,999 warrants of the Company outstanding. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161117006459/en/ Tetlin Phase III 2016 Core Holes Drilled (Graphic: Business Wire) The drilling conducted by Peak Gold, LLC, a joint venture between the Company and Royal Alaska, LLC (“Royal”), a wholly owned subsidiary of Royal Gold, Inc. managed by Royal (the “Joint Venture”) in the North Peak resource area of the Joint Venture’s gold exploration project […]

Read more...

Posted by admin - November 18, 2016 at 12:37 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , , , , , , , , , ,

Penny Stock News: Zoned Properties to Present at the 9th Annual LD Micro Main Event on December 7

Contact Us Journalists Blog Log In Sign Up Send a Release News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture Nov 14, 2016, 16:05 ET Preview: Zoned Properties Announces Third Quarter Results Release contains wide tables.View fullscreen. News in Focus Business & Money Science & Tech Lifestyle & Health Policy & Public Interest People & Culture PR Newswire: OTC, SmallCap

Read more...

Posted by admin - November 17, 2016 at 6:24 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , ,

Penny Stock News: Relmada Therapeutics, Inc. (RLMD: OTCQB) | Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum

NEW YORK, Oct. 6, 2016 /PRNewswire/ — Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that it will present at the 15th Annual BIO Investor Forum to be held October 18-19, 2016, at the Westin St. Francis, San Francisco. The presentation by Michael D. Becker, Chief Financial Officer of Relmada Therapeutics, is scheduled to begin at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time) on Tuesday, October 18. A live webcast of the presentation will be available through the Company’s website at www.relmada.com. Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and […]

Read more...

Posted by admin - October 6, 2016 at 1:05 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , ,

Penny Stock News: Fortescue Metals Group Ltd (FSUGY: OTCQX International Premier) | 2016 Notice of Annual General Meeting

2016 Notice of Annual General Meeting Oct 04, 2016 OTC Disclosure & News Service East Perth, WA, Australia This release includes additional documents. Select the link(s) below to view. 2016 Notice of Annual General Meeting with Proxy Sample.pdf Copyright © 2016 OTC Markets. All Rights Reserved The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases. OTC Markets Group – News, Filings & Corporate Actions

Read more...

Posted by admin - October 5, 2016 at 5:13 am

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , , , ,

Penny Stock News: CloudCommerce, Inc. (CLWD: OTCQB) | CloudCommerce Reports Over 300% Increase in Annual Revenue

SANTA BARBARA, CA–(Marketwired – September 30, 2016) – CloudCommerce, Inc. (OTCQB: CLWD), a global provider of advanced e-commerce services to leading brands, today announced the filing of its first annual report after the recent acquisition of Indaba Group (“Indaba”), with consolidated revenue showing substantial improvement over the previous year. Total revenue for the fiscal year ended June 30, 2016 increased by $ 1,481,398 to $ 2,079,743 compared to $ 598,345 for the fiscal year ended June 30, 2015. This approximate increase of 347% was primarily due to the acquisition of Indaba. “The acquisition of Indaba has proven to be a very beneficial transaction for us,” said CloudCommerce CEO Andrew Van Noy. “This annual report demonstrates the substantial impact Indaba has made on our year-over-year consolidated revenues. The Indaba team deserves credit for all their hard work. Moving forward, we will continue to pursue additional acquisitions to join our family of e-commerce companies and add shareholder value.” About CloudCommerce CloudCommerce, Inc. (OTCQB: CLWD) provides advanced e-commerce services to leading brands. Our customers depend on us to help them compete effectively in the $ 1.6 trillion worldwide e-commerce market. Our comprehensive services include: (1) development of highly customized and sophisticated online stores, […]

Read more...

Posted by admin - September 30, 2016 at 7:01 pm

Categories: Latest Penny Stock News   Tags: , , , , , , , , , , , ,

Next Page »